COST-EFFECTIVENESS ANALYSIS OF CRIZOTINIB VERSUS CHEMOTERAPY FOR FIRST LINE TREATMENT OF NONSMALL CELL LUNG CANCER ALK plus , FROM THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM PERSPECTIVE

被引：0
|
作者：
Ferreira, P. [1 ]
Senna, T. [1 ]
Sebastiao, M. [1 ]
Alexandre, R. F. [1 ]
Almeida, P. [1 ]
机构：
[1] Pfizer, Sao Paulo, SP, Brazil
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE52
引用
收藏
页码：S68 / S69
页数：2
相关论文
共 50 条
  • [41] ALK plus Non-Small Cell Lung Cancer Treated with First Line Crizotinib: Patient Characteristics, Treatment Patterns, and Survival
    Martin, C.
    Cardona, A.
    Arrieta, O.
    Castillo-Fernandez, O.
    Oblitas, G.
    Corrales, L.
    Lupinacci, L.
    Perez, M. A.
    Rojas, L.
    Gonzalez, L.
    Chirinos, L.
    Ortiz, C.
    Lema, M.
    Vargas, C.
    Puparelli, C.
    Carranza, H.
    Otero, J.
    Ramirez-Tirado, L.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1899 - S1900
  • [42] THE COST-EFFECTIVENESS OF SECOND-LINE CRIZOTINIB IN EML4-ALK REARRANGED ADVANCED NON-SMALL CELL LUNG CANCER
    Djalalov, S.
    Graham, D. M.
    Beca, J.
    Hoch, J. S.
    Tsao, M. S.
    Leighl, N.
    VALUE IN HEALTH, 2014, 17 (07) : A642 - A642
  • [43] Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1-rearranged advanced non-small cell lung cancer (NSCLC) in Canada
    Jaclyn M. Beca
    Shaun Walsh
    Kaiwan Raza
    Stacey Hubay
    Andrew Robinson
    Elena Mow
    James Keech
    Kelvin K. W. Chan
    BMC Cancer, 21
  • [44] Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1-rearranged advanced non-small cell lung cancer (NSCLC) in Canada
    Beca, Jaclyn M.
    Walsh, Shaun
    Raza, Kaiwan
    Hubay, Stacey
    Robinson, Andrew
    Mow, Elena
    Keech, James
    Chan, Kelvin K. W.
    BMC CANCER, 2021, 21 (01)
  • [45] Cost-effectiveness of alectinib compared with chemotherapy in first-line treatment for anaplastic lymphoma kinasepositive (ALK plus ) advanced non-small cell lung cancer in Thailand
    Sangroongruangsri, S.
    Kittrongsiri, K.
    ANNALS OF ONCOLOGY, 2022, 33 : S1556 - S1556
  • [46] Pembrolizumab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A Cost-Effectiveness Analysis
    Youwen Zhu
    Kun Liu
    Dong Ding
    Yangying Zhou
    Libo Peng
    Advances in Therapy, 2022, 39 : 2614 - 2629
  • [47] Pembrolizumab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A Cost-Effectiveness Analysis
    Zhu, Youwen
    Liu, Kun
    Ding, Dong
    Zhou, Yangying
    Peng, Libo
    ADVANCES IN THERAPY, 2022, 39 (06) : 2614 - 2629
  • [48] Cost-effectiveness analysis of durvalumab plus chemotherapy as first-line treatment for biliary tract cancer
    Ye, Zhuo-miao
    Xu, Zhe
    Li, Huan
    Li, Qian
    FRONTIERS IN PUBLIC HEALTH, 2023, 11
  • [49] Cost-effectiveness analysis of serplulimab combined with chemotherapy in the treatment of extensive-stage small-cell lung cancer from the perspective of the healthcare system in China
    Long, Yunchun
    Xu, Yuan
    Liao, Li
    Zhou, Yujie
    Wang, Hao
    BMJ OPEN, 2023, 13 (08):
  • [50] DOCETAXEL IN THE FIRST-LINE TREATMENT OF NON-SMALL-CELL LUNG CANCER: A COST-EFFECTIVENESS ANALYSIS VERSUS VINORELBINE FROM THE TAX 326 TRIAL
    Baillot, S.
    de Pouvourville, G.
    Morais, E.
    Scharzinger, M.
    Fossella, F.
    ANNALS OF ONCOLOGY, 2008, 19 : 227 - 227
12345